NEW YORK (AP) — European regulators have given orphan drug status to Aeterna Zentaris’ potential ovarian cancer treatment, the Canadian biotechnology company said Monday.
Orphan drug status is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market. Incentives in Europe include a quicker review process, reductions in regulatory fees and up to 10 years of market exclusivity for the drug.
Aeterna’s AEZS-108 already has orphan drug status in the U.S., which provides similar benefits, with up to seven years of market exclusivity.
